1. Home
  2. GEG vs ACET Comparison

GEG vs ACET Comparison

Compare GEG & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

GEG

Great Elm Group Inc.

HOLD

Current Price

$2.50

Market Cap

80.9M

Sector

Technology

ML Signal

HOLD

Logo Adicet Bio Inc.

ACET

Adicet Bio Inc.

HOLD

Current Price

$8.36

Market Cap

71.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GEG
ACET
Founded
1994
1947
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
80.9M
71.3M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
GEG
ACET
Price
$2.50
$8.36
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
$136.00
AVG Volume (30 Days)
92.2K
196.6K
Earning Date
02-04-2026
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.12
N/A
Revenue
$23,112,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$21.00
N/A
Revenue Growth
24.82
N/A
52 Week Low
$1.76
$7.15
52 Week High
$3.51
$17.76

Technical Indicators

Market Signals
Indicator
GEG
ACET
Relative Strength Index (RSI) 48.95 98.12
Support Level $2.38 $0.47
Resistance Level $2.50 $0.52
Average True Range (ATR) 0.11 0.15
MACD -0.01 0.78
Stochastic Oscillator 51.02 94.27

Price Performance

Historical Comparison
GEG
ACET

About GEG Great Elm Group Inc.

Great Elm Group Inc operates as an alternative asset manager focused on growing a scalable and diversified portfolio of long-duration and permanent capital vehicles across credit, real estate, specialty finance, and other alternative strategies. Along with its subsidiaries, it manages Great Elm Capital Corp, a publicly traded business development company, and Monomoy Properties REIT, LLC, an industrial-focused real estate investment trust, in addition to other investments.

About ACET Adicet Bio Inc.

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.

Share on Social Networks: